Objective: To observe and evaluate the efficacy of valproate on electroencephalography and obesity in children with epilepsy.
Methods: 109 children with epilepsy in our hospital were selected from September 2014 to October 2017, and randomly divided into the control group and the treatment group. 52 cases in the control group were treated with levetiracetam; and the other 57 cases in the treatment group received Valproate. The efficacy, the results of electroencephalography, the body mass index, the serum values of leptin, adiponectin, leptin/adiponectin of patients in the two groups were evaluated and compared.
Results: According to the patients’ clinical treated effects, the total effective rate in the treatment group was 87.72%, which was higher than the control group (P<0.05). After treatment for 6 months, the BMI, the serum value of leptin, leptin/adiponectin of patients in the treatment group were all higher than the control group and before treatment (P<0.05). Meanwhile, the serum value of adiponectin of patients in the treatment group was lower than the control group and before treatment (P<0.05).
Conclusion: It’s suggested that valproate improve the electroencephalography and clinical systems of children with epilepsy, but valproate induce the obesity which could be relative with the serum values of leptin, adiponectin, leptin/adiponectin.